Is Liquidia Corporation (NASDAQ:LQDA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Liquidia Corporation at current levels.
YUTREPIA's launch is rewriting the treprostinil market, and the Street is still anchored to United Therapeutics' rear-view mirror.
Where LQDA is headed
Liquidia exits 2027 as the dominant inhaled treprostinil franchise in the United States, with YUTREPIA running at roughly $700-800M in annualized revenue and L606 entering its commercial ramp. The setup is unusual. A company that did less than $20M in revenue in early 2025 is now compounding off a launch that physicians describe as the easiest switch story in pulmonary hypertension in a decade. Dry powder, no nebulizer, higher tolerated doses, fewer side effects. The clinical reasons patients and prescribers move off Tyvaso are not subtle, and the conversion data flowing out of academic centers since the May 2025 FDA approval has been faster than even bullish models assumed.
Read the full Compass Direction on LQDA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $75.49).
See the full LQDA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Liquidia Corporation (NASDAQ:LQDA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Liquidia Corporation at current levels. YUTREPIA's launch is rewriting the treprostinil market, and the Street is still anchored to United Therapeutics' rear-view mirror.
What is LQDA's Compass Score?
Liquidia Corporation scores 81/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for LQDA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the LQDA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.